ST. LOUIS, Feb. 1 /PRNewswire-FirstCall/ -- GenoMed, Inc. , a Next Generation Disease Management company, announced today that it can deliver better healthcare for half the cost, if coupled with the President’s health savings accounts (HSAs).
In his State of the Union address last night, President Bush called for wider use of HSAs. GenoMed agrees that HSAs will bring better, less expensive healthcare to all Americans, provided that Americans use their HSAs for GenoMed.
HSAs encourage spending for preventive medicine. Conventional health insurance plans, for a number of reasons, don’t spend a penny on prevention. Knowing the genes which cause disease allows more effective prevention than ever before. GenoMed is a pioneer in preventive molecular medicine. For example, GenoMed can prevent 90-95% of kidney dialysis in the US.
If a person uses their HSA to pay for GenoMed’s Next Generation Disease Management service, they can get the best preventive care in the world for about half the price of conventional health insurance.
Thanks to President Bush’s HSAs, GenoMed can now offer an insurance plan inexpensive enough to attract most of America’s 46 million uninsured patients. Given the high cost of healthcare, other customers should quickly follow, including large employers, state Medicaid programs, Medicare, overseas National Health Services, etc.
About GenoMed(TM)
GenoMed is leading the clinical revolution which knowledge of disease genes makes possible. GenoMed is currently marketing its protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema. The company is offering its Healthchip(R) on a research basis only to predict breast, colon, lung, ovarian, pancreatic, and prostate cancer in whites. And GenoMed is in the process of creating a virtual pharmaceutical company to develop the hundreds of cancer chemotherapy targets it has discovered.
Safe Harbor Statement
This press release contains forward-looking statements pertaining to GenoMed, Inc.'s (The Company’s) finances and treatments. The words or phrases “ought to, “should,” “could, “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties including, but not limited to our research and development being subject to economic, regulatory, governmental and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments unanticipated events or circumstances after the date of such statement.
GenoMed, Inc.
CONTACT: David Moskowitz MD, CEO of GenoMed, Inc., +1-314-983-9933,dwmoskowitz@genomed.com
Web site: http://www.genomed.com/
